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Background: Hepatitis B virus (HBV) infection is a serious global health problem. A lot of 
people are infected with HBV, and chronically infected individuals often come down with 
chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Though complete 
elimination of the virus is difficult, patients are generally treated with interferon or 
nucleot(s)ide analogue (NA) to suppress viral replication and prevent the progression of liver 
diseases. On that account Japanese guidelines recommend that the final goal of antiviral 
therapy should be serum hepatitis B surface antigen (HBsAg) loss but it is difficult to 
achieve that by long-term treatment with NAs. Recently pegylated-interferon (Peg-IFN) and 
NAs combination therapy is considered as an option for accelerating HBsAg reduction. 
However the best approach of Peg-IFN treatment for chronic hepatitis B patients during 
long term NA therapy has yet to be determined. 
Methods: Twenty-one HBe antigen-negative chronic hepatitis B patients whose HBV DNA 
were suppressed to undetectable levels by NA therapy, and have no evidence of other liver 
diseases and another viruses infection were administrated Peg-IFNα2a. Sequential therapy, 
which induced 48weeks of Peg-IFNα2A therapy (180μg/week) beginning one month prior to 
discontinuation of NA therapy until 11 months after, were underwent for 10 patients, and 
add-on therapy which induced 48weeks of Peg-IFNα2A that overlapped with NA for 11 
patients. Factors associated with HBsAg reduction by Peg-IFN therapy were analyzed. 
Results: During Peg-IFN treatment, no patient needed Peg-IFN dose reduction due to side 
effects. There was no significant difference among clinical factors at the beginning of 
Peg-IFN therapy between patients treated with sequential therapy and those treated with 
add-on therapy. During Peg-IFN treatment HBsAg levels were reduced by 0.48 Log IU/ml. 
More than 1 LogIU/ml of HBsAg reduction was observed in 8 patients (sequential therapy: 6, 
add-on therapy: 2), and one patient with sequential therapy achieved complete loss of 
HBsAg. By univariate analysis, sequential therapy was marginally associated with more 
than 1 LogIU/ml HBsAg reduction during Peg-IFN treatment (P=0.063). Duration of NA 
treatment, HBsAg, HB core related antigen (HBcrAg), and HBV DNA levels at the 
beginning of Peg-IFN treatment were not significant. In addition 5 patients (sequential 
therapy: 5, add-on therapy: 0), including the patient got HBsAg loss, achieved more than 0.5 
LogIU/ml of HBsAg reduction by 1 year after Peg-IFN treatment. By univariate analysis, 
only sequential therapy was significantly associated with HBsAg reduction after Peg-IFN 
treatment (P=0.012). ALT and HBsAg levels at the beginning of Peg-IFN therapy were 
marginally associated with that (P=0.050, P=0.062, respectively). As recently we proposed 
that upregulation of IL-8 in hepatocyte induced by HBV infection might lead to suppression 
of interferon responsiveness, we predicted that serum IL-8 levels might be associated with 
the antiviral effect of Peg-IFN. So we measured serum IL-8 at the beginning and the end of 
Peg-IFN therapy. Then lower serum IL-8 level at the end of Peg-IFN treatment were 
significantly associated with HBsAg reduction by 1 year after Peg-IFN treatment (P=0.044). 
In addition observing the time course of ALT during Peg-IFN therapy, HBsAg reduction 
levels from the beginning of Peg-IFN therapy to 1 year after the therapy were significantly 
correlated with the maximum ALT levels during Peg-IFN therapy (P=0.002). In patients 
whose ALT levels elevates more than 50 U/L during Peg-IFN therapy HBsAg levels were 
reduced significantly more in 1 year after Peg-IFN therapy than that in patients without 
ALT elevation (P=0.038). There was no significant association between serum IL-8 at the 
beginning and end of Peg-IFN therapy and ALT elevation during Peg-IFN therapy (P=0.533, 
P=0.203, respectively). 
Discussion: Marcellin et al. showed the superiority of TDF and Peg-IFNα2A combination 
therapy than their monotherapy for inducing HBsAg loss of chronic hepatitis B patients 
with no history of NA treatment in their study. However it is unclear whether add-on 
therapy is superior to sequential therapy for HBsAg reduction. In our study sequential 
therapy brought the reduction of HBsAg not only during the Peg-IFN treatment but also 1 
year after the treatment, whereas HBsAg levels in most patients who were treated with 
add-on therapy were not reduced drastically. We hypothesized that host immune responses 
might be activated by the cessation of NA therapy and activated immuno response could 
help bolster the antiviral effects of Peg-IFN leading to reduction of HBsAg. ALT elevation 
during Peg-IFN therapy and lower IL-8 level at the end of Peg-IFN therapy may support the 
idea. Although the number of study subjects was small, our results support the need for 
establishing strategies for inducing HBsAg loss in chronic hepatitis B patients. 
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